40th European Association for the Study of the Liver (EASL)

13-17 April 2005, Paris, France

An excellent selection of over 20 reports from this important European meeting are available on the NATAP website, including:

  • Incidence and predictors of emergence of resistance to adefovir after 4 years follow-up
  • Age & ribavirin dose reductions reduce SVR to peginterferon+ribavirin
  • Cost effectiveness of peginterferon in HCV/HIV coinfection
  • Albuferon: new HCV drug
  • New HCV drug NM283: 24 week data at EASL
  • New HCV drugs in development: EASL Report

Links to other websites are current at date of posting but not maintained.